Cardiol Therapeutics Inc Class A
$ 1.00
1.93%
24 Feb - close price
- Market Cap 110,117,000 USD
- Current Price $ 1.00
- High / Low $ 1.03 / 0.99
- Stock P/E N/A
- Book Value 0.08
- EPS -0.30
- Next Earning Report 2026-03-30
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -1.49 %
- ROE -3.48 %
- 52 Week High 1.59
- 52 Week Low 0.77
About
Cardiol Therapeutics Inc., a clinical-phase biotechnology company, focuses on the research and development of anti-inflammatory therapies for the treatment of cardiovascular diseases (CVD). The company is headquartered in Oakville, Canada.
Analyst Target Price
$7.46
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-18 | 2025-08-19 | 2025-05-12 | 2025-03-31 | 2024-11-12 | 2024-08-12 | 2024-04-01 | 2024-03-28 | 2023-11-14 | 2023-08-10 | 2023-05-15 | 2023-03-30 |
| Reported EPS | -0.0857 | -0.0722 | -0.1 | -0.09 | -0.18 | -0.1 | -0.12 | -0.09 | -0.09 | -0.12 | -0.11 | -0.12 |
| Estimated EPS | -0.0775 | -0.0997 | -0.08 | -0.1167 | -0.08 | -0.13 | -0.12 | -0.09 | -0.12 | -0.12 | -0.15 | -0.15 |
| Surprise | -0.0082 | 0.0275 | -0.02 | 0.0267 | -0.1 | 0.03 | 0 | 0 | 0.03 | 0 | 0.04 | 0.03 |
| Surprise Percentage | -10.5806% | 27.5827% | -25% | 22.8792% | -125% | 23.0769% | 0% | 0% | 25% | 0% | 26.6667% | 20% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-30 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.09 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CRDL
2026-02-11 11:27:59
Cardiol Therapeutics announced the publication of its Phase II ARCHER study results in ESC Heart Failure, revealing that CardiolRx significantly reduced left ventricular mass and showed favorable trends in myocardial inflammation markers in 109 patients with acute myocarditis. These findings are considered relevant to the ongoing pivotal Phase III MAVERIC trial for recurrent pericarditis. The treatment was also reported as safe and well-tolerated.
2026-02-01 00:32:36
Cardiol Therapeutics Inc. announced the results of its 2025 Annual General Meeting of Shareholders, where all Management resolutions were approved. Dr. Timothy Garnett was elected to the Board of Directors, bringing extensive drug development and commercial expertise to the company. The company also provided updates on its clinical trials for CardiolRx™ in recurrent pericarditis and acute myocarditis, and the development of CRD-38 for heart failure.
2026-01-29 11:27:58
Cardiol Therapeutics has secured approximately $14.85 million through a bought-deal private placement. The financing involves issuing 11.4 million units at $1.30 per unit, each including one common share and a half-warrant exercisable at $1.75. This move aims to strengthen the company's financial position, though Spark's AI Analyst maintains a Neutral rating due to weak financial performance and high dilution risk.
2026-01-25 23:27:11
Cardiol Therapeutics has secured a $13.5 million bought-deal private placement to fund its research and clinical development programs for inflammatory heart disease. The financing, which includes an over-allotment option for an additional $1.35 million, will support late-stage cardiovascular trials. Despite weak financial performance and a "Neutral" rating from TipRanks' AI Analyst, the company aims to strengthen its competitive position, focusing on its lead drug candidate, CardiolRx, for conditions like pericarditis and myocarditis.
2026-01-25 11:30:30
Cardiol Therapeutics Inc. successfully closed a funding round, receiving CAD 14.85 million through the issuance of 11,423,078 units at CAD 1.30 per unit. This figure includes the full exercise of an overallotment option by the underwriter. The company paid a 6% cash commission on the gross proceeds, and the offering was conducted via a private placement, with units exempt from Canadian resale restrictions.
2026-01-24 00:58:48
Cardiol Therapeutics announced the closing of a private placement, raising $14.85 million through the issuance of 11,423,078 Units at $1.30 per Unit, including the full exercise of an over-allotment option. The net proceeds are earmarked for advancing research and clinical development programs, as well as covering general and administrative expenses and working capital. This financing supports the company's ongoing efforts to develop anti-inflammatory and anti-fibrotic therapies for heart disease.
